Abstract
In Crohn’s disease the optimal duration of azathioprine treatment is still controversial and for ulcerative colitis only limited data are available to support its efficacy. Charts of 1176 patients with IBD from 16 European centers were analyzed. Flare incidences and steroid dosages were assessed for the time before and during treatment and after discontinuation. Within the first 4 years, azathioprine suppressed flare incidence and steroid consumption in both diseases (P < 0.001). While in CD discontinuation after 3–4 years did not lead to reactivation, this was the case in UC. However, continuation beyond 4 years further improved clinical activity in CD and steroid requirement in both diseases (P < 0.001). Discontinuation of azathioprine may thus be considered after 3–4 years in CD patients in complete remission without steroid requirement. In all other CD patients and for UC patients in general, continuation seems beneficial. These results support a novel differential algorithm for long-term azathioprine therapy in IBD.
Similar content being viewed by others
References
Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C (2000) Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2:CD000545
Pearson DC, May GR, Fick G, Sutherland LR (2000) Azathioprine for maintaining remission of Crohn’s disease. Chochrane Database Syst Rev
Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R (1995) A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 5:674–678
Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC (1996) Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 347:215–219
Kim PS, Zlatanic J, Korelitz BI, Gleim GW (1999) Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease. Am J Gastroenterol 11:3254–3257
Kirk AP, Lennard-Jones JE (1982) Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1291–1292
Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB (1975) A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1:96–99
Jewell DP, Truelove SC (1974) Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 5945:627–630
Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE (1992) Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 6844:20–22
Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G, Molteni F (1997) Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 330–333
Theodor E, Niv Y, Bat L (1981) Imuran in the treatment of ulcerative colitis. Am J Gastroenterol 262–266
Steinhart AH, Baker JP, Brzezinski A, et al. (1990) Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol 271–275
Fraser AG, Orchard TR, Jewell DP (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 485–489
Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle P, Ahmadian MR (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 1133–1145
Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W (2004) Nonclassical CD1d-restricted NK T cells that produced IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 1490–1497
Neurath MF, Finotto S, Glimcher LH (2002) The role of Th1/Th2 polarization in mucosal immunity. Nat Med 6:567–573
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Holtmann, M.H., Krummenauer, F., Claas, C. et al. Long-Term Effectiveness of Azathioprine in IBD Beyond 4 Years: A European Multicenter Study in 1176 Patients. Dig Dis Sci 51, 1516–1524 (2006). https://doi.org/10.1007/s10620-005-9037-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-9037-5